Ottimopharma
Founded 2020 · 20 employees on LinkedIn · 2 known investors
Ottimo Pharma is a clinical-stage biotech company developing PD-1/VEGFR2 dual-paratopic antibodies for cancer treatment. Its lead candidate, OTP-01, is being tested in a Phase I/IIA study across oncology centers in the US and Australia.
Investors · 2
Frequently asked questions
- What does Ottimopharma do?
- Ottimo Pharma is a clinical-stage biotech company developing PD-1/VEGFR2 dual-paratopic antibodies for cancer treatment. Its lead candidate, OTP-01, is being tested in a Phase I/IIA study across oncology centers in the US and Australia.
- Who are Ottimopharma's investors?
- Ottimopharma's investors include Avoro Capital Advisors, OrbiMed.